Results 71 to 80 of about 11,732 (171)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma

Therapeutic Advances in Medical Oncology, 2020
Background: Despite the scarcity of data based on randomized trials, FOLFIRINOX is widely used in the management of borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC).
Changhoon Yoo, Inhwan Hwang, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jae Ho Byun, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Heung-Moon Chang, Kyu-pyo Kim, Song Cheol Kim, Baek-Yeol Ryoo   +18 more
doaj   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, Volume 13, Issue 54, 28 September 2026.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy

, 2020
International audienceBackground - Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil [5FU], folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance ...
El Hajbi, Farid, Chevalier, Hortense, Meurisse, Aurélia, Edeline, Julien, Peugniez, Charlotte, Neuzillet, Cindy, Borg, Christophe, Vernerey, Dewi, Vienot, Angélique, Hammel, Pascal, Lièvre, Astrid, Turpin, Anthony   +11 more
core   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma.

, 2017
484 Background: The treatment of advanced biliary tract adenocarcinoma is based on chemotherapy with Gemcitabine with Cisplatin or Oxaliplatin in various combinations. After seeing the high efficacy of FOLFIRINOX regimen in advanced pancreatic cancers,
Amit Rauthan, Poonam Patil
core   +1 more source

Эффективность и безопасность индукционной химиотерапии по схеме FOLFIRINOX при погранично резектабельном и нерезектабельном раке поджелудочной железы [PDF]

, 2018
Objective. To evaluate efficacy and safety of FOLFIRINOX regimen as induction therapy in borderline resectable and unresectable pancreatic cancer.Materials and methods.
И. С. Базин, И. А. Файнштейн, A. G. Kotelnikov, Р. К. Валиев, I. V. Sagaydak, Н. Е. Кудашкин, С. А. Тюляндин, I. A. Pokataev, I. A. Fainstein, M. Yu. Fedyanin, А. Г. Котельников, A. S. Popova, I. A. Gladilina, D. A. Chekini, S. A. Tjulandin, Kh. Kh. M. Elsnukaeva, И. А. Гладилина, И. В. Сагайдак, M. G. Abgaryan, S. B. Alieva, N. E. Kudashkin, Д. А. Чекини, R. K. Valiev, I. S. Bazin, И. А. Покатаев, Х. Х. Эльснукаева, D. V. Podluzhny, A. V. Nazarenko, М. Г. Абгарян, А. В. Назаренко, O. V. Sehina, Д. В. Подлужный, С. Б. Алиева, О. В. Сехина, А. С. Попова, М. Ю. Федянин   +35 more
core   +1 more source

Pankreatobiliyer karsinoma tedavisinde folfirinox kemoterapisinin etkinliği ve toleransı

, 2018
Özet: Bu çalışmanın amacı oksaliplatin, irinotekan, florourasil ve lökoverin kombinasyon tedavisinden oluşan FOLFIRINOX tedavisi ile gemsitabin- sisplatin kombinasyon tedavisinin pankreatobiliyer kanserli hastalardaki etkinlik ve güvenliklerini ...
NESLİHAN KAYAHAN SATIŞ
core   +1 more source

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy

Clinical and Translational Radiation Oncology
Background: To evaluate the efficacy and optimal timing of local treatment in patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) treated with upfront FOLFIRINOX.
Kangpyo Kim, Hee Chul Park, Jeong Il Yu, Joon Oh Park, Jung Yong Hong, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Seok Heo, Sang Hyun Shin, Ji Hye Min, Kyunga Kim, In Woong Han   +13 more
doaj   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains ...
Kenji Ikezawa, Toshihiro Imai, Ryoji Takada, Takuo Yamai, Nobuyasu Fukutake, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Kazuyoshi Ohkawa   +9 more
wiley   +1 more source

Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)

EClinicalMedicine, 2019
Background: We conducted a multicentre phase II trial to investigate feasibility and antitumor activity of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC), (LAPC-1 trial). Methods:
Mustafa Suker, Joost J. Nuyttens, Ferry A.L.M. Eskens, Brigitte C.M. Haberkorn, Peter-Paul L.O. Coene, Erwin van der Harst, Bert A. Bonsing, Alexander L. Vahrmeijer, J.Sven D. Mieog, Rutger Jan Swijnenburg, Daphne Roos, B.Groot. Koerkamp, Casper H.J. van Eijck   +12 more
doaj   +1 more source